Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page now displays Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision: v3.4.3 has been added, replacing the previous v3.4.2. This is a minor UI/version update and does not change study details or user interactions on the page.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision: v3.4.2 is now shown; notices about government funding lapses and Revision: v3.4.1 respectively have been removed.SummaryDifference0.3%

- Check77 days agoChange DetectedAdded a notice about a lapse in government funding and updated the revision to v3.4.1. The previous revision v3.4.0 was removed.SummaryDifference0.3%

- Check84 days agoChange DetectedAdded a glossary display option and updated several labels to capitalize consistently (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and updated the revision tag from v3.3.4 to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.